Passive haemovigilance of blood components treated with a riboflavin-based pathogen reduction technology

被引：10
|
作者：
Piotrowski, Dariusz [1 ]
Przybylska-Baluta, Zofia [1 ]
Jimenez-Marco, Teresa [2 ]
Kryzauskaite, Lina [3 ]
Papachronis, Andreas [4 ]
Marinaki, Aliki [4 ]
Hoecker, Paul [5 ]
Cherrier-De Wilde, Sigrid [6 ]
Cardoso, Marcia [7 ]
机构：
[1] Reg Blood Transfus Ctr, Warsaw, Poland
[2] Blood & Tissue Bank Fdn Balear Isl, Palma De Afallorra, Spain
[3] Vilnius Univ Hosp Santariskiu Klin, Vilnius, Lithuania
[4] Laiko Hosp, Athens, Greece
[5] EUROPLASMA, Vienna, Austria
[6] Ctr Hosp Luxembourg, Luxembourg, Luxembourg
[7] Terumo BCT Europe, Zaventem, Belgium
来源：
BLOOD TRANSFUSION | 2018年 / 16卷 / 04期
关键词：
haemovigilance; pathogen reduction technology; blood components; TRANSFUSIONS;
D O I：
10.2450/2017.0268-16
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：348 / 351
页数：4
相关论文
共 50 条
  • [1] Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white blood cell inactivation
    Reddy, Heather L.
    Dayan, Anthony D.
    Cavagnaro, Joy
    Gad, Shayne
    Li, Junzhi
    Goodrich, Raymond P.
    [J]. TRANSFUSION MEDICINE REVIEWS, 2008, 22 (02) : 133 - 153
  • [2] Improving the safety of whole blood-derived transfusion products with a riboflavin-based pathogen reduction technology
    Yonemura, Susan
    Doane, Suzann
    Keil, Shawn
    Goodrich, Raymond
    Pidcoke, Heather
    Cardoso, Marcia
    [J]. BLOOD TRANSFUSION, 2017, 15 (04) : 357 - 364
  • [3] Mirasol™ pathogen reduction technology:: Riboflavin-based process retains functional activities of immunoglobulins
    Kumar, V
    Motheral, T
    Luzniak, G
    Monique, J
    Goodrich, R
    [J]. TRANSFUSION, 2003, 43 (09) : 80A - 80A
  • [4] THE COST-UTILITY OF RIBOFLAVIN-BASED PATHOGEN REDUCTION TECHNOLOGY FOR PLATELETS AND PLASMA: A PRELIMINARY ANALYSIS
    Custer, S.
    Agapova, M.
    [J]. VOX SANGUINIS, 2010, 99 : 259 - 259
  • [5] Mirasol™ plasma pathogen reduction technology:: Riboflavin-based process conserves protein C, protein S and antithrombin activities
    Kumar, V
    Motheral, T
    Luzniak, G
    Janssens, M
    Goodrich, R
    [J]. TRANSFUSION, 2003, 43 (09) : 80A - 80A
  • [6] A novel riboflavin-based pathogen reduction system does not introduce neoantigens in human platelets.
    Piper, JT
    Woolum, MD
    Burleson, EG
    Burleson, GR
    Goodrich, RP
    [J]. TOXICOLOGICAL SCIENCES, 2003, 72 : 332 - 332
  • [7] Viral inactivation in plasma using riboflavin-based technology
    Samar, BM
    Goodrich, RP
    Services, V
    [J]. TRANSFUSION, 2001, 41 (09) : 88S - 88S
  • [8] Pathogen reduction of blood components
    Solheim, Bjarte G.
    [J]. TRANSFUSION AND APHERESIS SCIENCE, 2008, 39 (01) : 75 - 82
  • [9] Mirasol™ pathogen reduction technology for blood products using riboflavin and UV illumination:: Mode of action of riboflavin on pathogen nucleic acid chemistry
    Kumar, V
    McLean, R
    Keil, S
    Gilmour, D
    Luzniak, G
    Lockerbie, O
    Rice, J
    Jansenns, M
    Goodrich, R
    [J]. TRANSFUSION, 2003, 43 (09) : 79A - 79A
  • [10] Pathogen Reduction Technology Treatment of Platelets, Plasma and Whole Blood Using Riboflavin and UV Light
    Marschner, Susanne
    Goodrich, Raymond
    [J]. TRANSFUSION MEDICINE AND HEMOTHERAPY, 2011, 38 (01) : 8 - 18
12345